Documents

Rare disease growth and new indications drive robust outlook, with 2025 targets on track.

Strong 2025 growth driven by rare disease, robust margins, and strategic partnerships.

Rare disease growth accelerates, Isturisa guidance raised, and 2026 set as a key investment year.

Isturisa’s peak sales target doubled as rare disease and U.S. growth drive strong results.

Double-digit revenue and EBITDA growth, with rare diseases nearing 40% of total revenue.

Q1 revenue up 11.9% to €680M, EBITDA margin 39.7%, 2025 and 2027 growth targets confirmed.

Revenue set to double by 2030, with robust growth in specialty care and rare diseases.

Rare disease growth, disciplined M&A, and new product launches drive strong 2025 outlook.

Double-digit growth in 2024 sets the stage for higher margins and robust 2025 guidance.

Rare disease growth, strategic biotech exits, and 2025 IPO optimism dominated discussions.

Double-digit revenue and profit growth, strong cash flow, and guidance confirmed for 2024.

Acquisition of Enjaymo boosts rare disease portfolio, with strong growth and margin outlook.